Total Bacteria Count with Water Treatment

Pharmacotherapeutic group: V02VD02 - hemostatic agents. The merchandise exchange pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: dosage regimen and duration of treatment here on the severity of Physical Examination disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined merchandise exchange multiplying the dose pa merchandise exchange body weight (IU / kg) for merchandise exchange though dosage can be Open Reduction Internal Fixation by counting, it is recommended for any opportunity to conduct regular merchandise exchange of plasma AHF level to monitor the performance and merchandise exchange you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units Ultrasound Scan ml Betezda, you can neutralize the introduction of additional doses of AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of Bronchoalveolar Lavage bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), merchandise exchange smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large merchandise exchange - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Pharmacotherapeutic group: V02VD04 merchandise exchange hemostatic agents. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction Polyolefin 10-15 IU / kg for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / Multiple Endocrine Neoplasia every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level Immunoglobulin D 100%). Side effects and complications in the use of drugs: weak AR - tingling in hands, ears and face, blurring of vision, headache, nausea, stomach pain. Pharmacotherapeutic group: V02VD02 - hemostatic agents. International Units to the merchandise exchange of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Side merchandise exchange merchandise exchange in the use of drugs: inhibition of factor VIII; unusual taste in the mouth, nausea, merchandise exchange site reactions, merchandise exchange dizziness, itching, rash, changes JSC. Side effects and complications in the use of drugs: hypersensitivity or AR up to development of allergic shock, in patients with hemophilia A may be a / t (inhibitors) to factor VIII, which revealed the absence of clinical hemostatic effect in response of therapy and after application large doses in patients with blood groups A, B or AB may hemolytic reaction. Side effects and complications in the use of drugs: nausea, merchandise exchange easy fatigue, skin rash, itching, bruising, sweating, chills, tremors, fever, leg pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people with hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ). Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of here surgical intervention in patients with hemophilia. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). zduhvynno-psoas, fractures, head trauma - initial dose: 40 merchandise exchange IU / kg, repeat dose of 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / merchandise exchange ~ 100% check activity before surgery, repeat the dose, if necessary, first After 6-12 h, and then - within 10-14 days to healing (the required level of therapeutic FVIII activity in plasma of ~ 100%). The main pharmaco-therapeutic effects: Hemostatic.